Abstract
Depression is one of the most common psychiatric conditions affecting numerous individuals in the world. However, the currently available antidepressant medication shows low response and remission rates. Thus, new antidepressants need to be discovered or developed. Aiming to describe the current neurobiological hypotheses regarding the pathophysiology of depression and in order to give an overview of novel possible antidepressant drug targets, we reviewed publications and studies referring to the neurobiology of depression. This review included genetics, epigenetics and gene expression, neuroanatomy and structural anatomy, neurochemistry, neuroendocrinology, neuroimmunology and novel drug targets using a MEDLINE/Pubmed search. The search was augmented by a manual search of bibliographies, textbooks, and abstracts from recent scientific meetings. On the one hand, the literature reveals in part contradictory information, but on the other hand, it shows convergent information regarding the relevance of research targets apart from the monoamine deficiency hypothesis of depression such as epigenetic phenomena and changes in neuronal and glial function and structure. Recent neurobiological findings in these areas of research provide multidimensional perspectives for the progress in the psychopharmacological treatment of depression.
Keywords: Neurobiology, depression, genetics, epigenetics, neurochemistry, neuroendocrinology, neuroimmunology, antidepressants, novel drug targets.
Current Pharmaceutical Design
Title:Neurobiology of Depression and Novel Antidepressant Drug Targets
Volume: 18 Issue: 36
Author(s): Nikola Kern, Abigail J. Sheldrick, Frank M. Schmidt and Juliane Minkwitz
Affiliation:
Keywords: Neurobiology, depression, genetics, epigenetics, neurochemistry, neuroendocrinology, neuroimmunology, antidepressants, novel drug targets.
Abstract: Depression is one of the most common psychiatric conditions affecting numerous individuals in the world. However, the currently available antidepressant medication shows low response and remission rates. Thus, new antidepressants need to be discovered or developed. Aiming to describe the current neurobiological hypotheses regarding the pathophysiology of depression and in order to give an overview of novel possible antidepressant drug targets, we reviewed publications and studies referring to the neurobiology of depression. This review included genetics, epigenetics and gene expression, neuroanatomy and structural anatomy, neurochemistry, neuroendocrinology, neuroimmunology and novel drug targets using a MEDLINE/Pubmed search. The search was augmented by a manual search of bibliographies, textbooks, and abstracts from recent scientific meetings. On the one hand, the literature reveals in part contradictory information, but on the other hand, it shows convergent information regarding the relevance of research targets apart from the monoamine deficiency hypothesis of depression such as epigenetic phenomena and changes in neuronal and glial function and structure. Recent neurobiological findings in these areas of research provide multidimensional perspectives for the progress in the psychopharmacological treatment of depression.
Export Options
About this article
Cite this article as:
Kern Nikola, Sheldrick J. Abigail, Schmidt M. Frank and Minkwitz Juliane, Neurobiology of Depression and Novel Antidepressant Drug Targets, Current Pharmaceutical Design 2012; 18 (36) . https://dx.doi.org/10.2174/138161212803523581
DOI https://dx.doi.org/10.2174/138161212803523581 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Sensitivity of Tyrosine Hydroxylase Activity and Expression in Dopaminergic Dysfunction
CNS & Neurological Disorders - Drug Targets Axonal Ionic Pathophysiology in Human Peripheral Neuropathy and Motor Neuron Disease
Current Neurovascular Research Cannabinoids and Parkinsons Disease
CNS & Neurological Disorders - Drug Targets The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Targeted Vascular Drug Delivery in Cerebral Cancer
Current Pharmaceutical Design Fish and Apoptosis: Studies in Disease and Pharmaceutical Design
Current Pharmaceutical Design Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy An Overview of Drug Screening Using Primary and Embryonic Stem Cells
Combinatorial Chemistry & High Throughput Screening Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design Biochemical, Molecular and Epigenetic Mechanisms of Valproic Acid Neuroprotection
Current Molecular Pharmacology In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) The Potential Role of Glycogen Synthase Kinase 3 Inhibitors as Amyotrophic Lateral Sclerosis Pharmacological Therapy
Current Medicinal Chemistry Therapeutic Implications of Superoxide Dismutase And Its Importance in Kinase Drug Discovery
Current Topics in Medicinal Chemistry Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning
Current Neuropharmacology PPAR-γ: Therapeutic Prospects in Parkinson's Disease
Current Drug Targets Discovering New Treatments for Alzheimer's Disease by Repurposing Approved Medications
Current Topics in Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Contribution of Analytical Microscopies to Human Neurodegenerative Diseases Research (PSP and AD)
Mini-Reviews in Medicinal Chemistry Human PON Promoters: From Similarity to Prediction of Polymorphic Positions within Transcription Factor Elements
Mini-Reviews in Medicinal Chemistry The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry